Loading
Nanjing Leads Biolabs is a Hong Kong-listed Chinese biotechnology company running 8 late-stage cancer trials of LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer and hepatocellular carcinoma.
Nanjing Leads Biolabs, based in Nanjing, China, is a biotechnology company founded in 2012 that listed on the Hong Kong Stock Exchange on 25 July 2025. In August 2026 China's drug regulator accepted, with priority review, its application to market LBL-024 (opamtistomig), a bispecific antibody against PD-L1 and 4-1BB, for previously treated advanced extrapulmonary neuroendocrine carcinoma. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer, hepatocellular carcinoma, oesophageal cancer and multiple myeloma. The largest, NCT05170958 (A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumours), plans to enrol 396 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · Hong Kong Main Board listing on 25 July 2025: 42,391,800 H shares at HK$35.00 including the over-allotment; net proceeds about HK$1,363.1 million as stated in the 2025 annual report; no USD figure given | 2025 | undisclosed | www1.hkexnews.hk |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/